Key Points Revenue (GAAP) exceeded analyst expectations by 9.3%, reaching $4.1 million, up 32% from the prior year period. Operating expenses fell 21%, narrowing the net loss compared to Q2 2024.

Achieved record-high quarterly revenues since inceptionIncreased 2025 financial guidance MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a ...

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of enterprise performance management, carrier service assurance, ...

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...

Find out what's happening with today's mortgage rates and calculate monthly repayments across a range of different rates and ...